KR20100087283A - 항­ｒｓｖ 항체의 재조합 제조 방법 - Google Patents

항­ｒｓｖ 항체의 재조합 제조 방법 Download PDF

Info

Publication number
KR20100087283A
KR20100087283A KR1020107007563A KR20107007563A KR20100087283A KR 20100087283 A KR20100087283 A KR 20100087283A KR 1020107007563 A KR1020107007563 A KR 1020107007563A KR 20107007563 A KR20107007563 A KR 20107007563A KR 20100087283 A KR20100087283 A KR 20100087283A
Authority
KR
South Korea
Prior art keywords
ser
thr
val
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107007563A
Other languages
English (en)
Korean (ko)
Inventor
안네 본드가아르드 톨스트럽
조한 란토
핀 비베르크
라르스 소에가아르드 닐센
Original Assignee
심포젠 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 심포젠 에이/에스 filed Critical 심포젠 에이/에스
Publication of KR20100087283A publication Critical patent/KR20100087283A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020107007563A 2007-09-07 2008-09-04 항­ｒｓｖ 항체의 재조합 제조 방법 Withdrawn KR20100087283A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200701289 2007-09-07
DKPA200701289 2007-09-07
US97140407P 2007-09-11 2007-09-11
US60/971,404 2007-09-11

Publications (1)

Publication Number Publication Date
KR20100087283A true KR20100087283A (ko) 2010-08-04

Family

ID=40297785

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107007563A Withdrawn KR20100087283A (ko) 2007-09-07 2008-09-04 항­ｒｓｖ 항체의 재조합 제조 방법

Country Status (13)

Country Link
US (2) US20090137003A1 (https=)
EP (1) EP2185590A2 (https=)
JP (1) JP2011514139A (https=)
KR (1) KR20100087283A (https=)
CN (1) CN101821289A (https=)
AU (1) AU2008295248A1 (https=)
BR (1) BRPI0817079A2 (https=)
CA (1) CA2695309A1 (https=)
MX (1) MX2010002044A (https=)
RU (1) RU2010113510A (https=)
TW (1) TW200925279A (https=)
WO (1) WO2009030237A2 (https=)
ZA (1) ZA201000756B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2444695T3 (es) * 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
DK2121920T3 (da) * 2007-03-01 2011-11-21 Symphogen As Fremgangsmåde til kloning af sammenhørende antistoffer
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CN102137928A (zh) * 2008-08-29 2011-07-27 西福根有限公司 克隆禽源抗体的方法
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5762408B2 (ja) * 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
EP2486053B1 (en) * 2009-10-06 2017-01-18 Medimmune Limited Rsv-specific binding molecule
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN104628850B (zh) * 2009-10-06 2020-07-28 医学免疫有限公司 Rsv-特异性结合分子
ES2724975T3 (es) 2009-12-10 2019-09-18 Regeneron Pharma Ratones que producen anticuerpos de cadena pesada
BR112012031638B1 (pt) 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
TWI606063B (zh) * 2012-08-23 2017-11-21 艾澤西公司 結合至１５８ｐ１ｄ７蛋白之抗體藥物結合物（ａｄｃ）
JP5996707B2 (ja) * 2015-04-15 2016-09-21 メディミューン リミテド Ｒｓｖ特異的結合分子
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
MA43389A (fr) * 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
AU2016364891A1 (en) * 2015-12-03 2018-06-07 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
CN110035771B (zh) * 2016-10-21 2024-03-08 阿迪马布有限责任公司 抗呼吸道合胞病毒抗体及其产生和使用方法
AU2017345786B2 (en) 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
WO2018150029A1 (en) * 2017-02-17 2018-08-23 Institut Pasteur Generation of monoclonal antibodies targeting respiratory syncytial virus (rsv) using regulatory b cells from newborns (nbregs)
CN113728003A (zh) 2019-04-30 2021-11-30 吉加根公司 重组多克隆蛋白及其使用方法
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
WO2021253002A1 (en) 2020-06-12 2021-12-16 Gigagen, Inc. Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2022031834A1 (en) * 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US8288109B2 (en) * 2004-07-20 2012-10-16 Symphogen A/S Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
EA014182B1 (ru) * 2004-07-20 2010-10-29 Симфоген А/С КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ
US7850965B2 (en) * 2005-12-05 2010-12-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
JP2010534057A (ja) * 2007-03-06 2010-11-04 シムフォゲン・アクティーゼルスカブ 呼吸器合胞体ウイルス感染症を治療するための組換え抗体
MX2009012526A (es) * 2007-05-25 2009-12-09 Symphogen As Metodo para fabricar una proteina policlonal recombinante.

Also Published As

Publication number Publication date
CN101821289A (zh) 2010-09-01
BRPI0817079A2 (pt) 2016-10-11
CA2695309A1 (en) 2009-03-12
US20090137003A1 (en) 2009-05-28
WO2009030237A2 (en) 2009-03-12
RU2010113510A (ru) 2011-10-20
AU2008295248A1 (en) 2009-03-12
ZA201000756B (en) 2010-10-27
JP2011514139A (ja) 2011-05-06
EP2185590A2 (en) 2010-05-19
WO2009030237A3 (en) 2009-04-30
TW200925279A (en) 2009-06-16
MX2010002044A (es) 2010-03-18
US20120009623A1 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
KR20100087283A (ko) 항­ｒｓｖ 항체의 재조합 제조 방법
AU2019246763B2 (en) Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
CN109414455B (zh) Bcma结合分子及其使用方法
KR20080113223A (ko) 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
KR101418606B1 (ko) Ｈｅｒ-３ 지향 항체 및 그 용도
KR20090127341A (ko) 호흡기세포 융합 바이러스 감염 치료용 재조합 항체
KR20070038556A (ko) 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법
US7141653B2 (en) Human monoclonal antibodies to interleukin-5
KR20230002261A (ko) 항-sars-cov-2 중화 항체 및 이의 사용 방법
AU2016200359B2 (en) Neutralizing Anti-CCL20 Antibodies
TWI320716B (en) Erythropoietin receptor binding antibodies
CN112262156B (zh) 抗her2抗体
KR20090088936A (ko) 사람 델타 유사 리간드 4에 대한 사람 항체
KR20120056863A (ko) Ｃｄ25에 대한 인간 모노클로날 항체
CN114685652B (zh) 针对SARS-CoV-2和SARS-CoV的全人广谱交叉中和抗体及其应用
CN113402602B (zh) 一种新型冠状病毒SARS-CoV-2中和性抗体及应用
KR101900435B1 (ko) 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체
CN113817057A (zh) 一种抗siglec15抗体及其应用
CN101023101A (zh) 抗－恒河猴d重组多克隆抗体和生产方法
CN114685653B (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
US12358971B2 (en) Arena virus monoclonal antibodies and uses
AU2004236263A1 (en) Compositions and methods for treatment of cryptococcosis
KR20110047258A (ko) 저혈소판증의 치료 방법
HK40000650B (en) Bcma binding molecules and methods of use thereof
MXPA05011989A (en) Compositions and methods for treatment of cryptococcosis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100407

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid